A140410 Stock Overview
Engages in the development, manufacturing, and sale of pharmaceutical products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Mezzion Pharma Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩30,900.00 |
| 52 Week High | ₩50,200.00 |
| 52 Week Low | ₩27,000.00 |
| Beta | 0.67 |
| 11 Month Change | 0.98% |
| 3 Month Change | -7.49% |
| 1 Year Change | -16.71% |
| 33 Year Change | -51.47% |
| 5 Year Change | -38.41% |
| Change since IPO | 211.60% |
Recent News & Updates
Here's Why We're Not Too Worried About Mezzion PharmaLtd's (KOSDAQ:140410) Cash Burn Situation
Nov 02
Mezzion Pharma Co.,Ltd.'s (KOSDAQ:140410) Shareholders Might Be Looking For Exit
Sep 27Revenues Not Telling The Story For Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
Jun 11Recent updates
Here's Why We're Not Too Worried About Mezzion PharmaLtd's (KOSDAQ:140410) Cash Burn Situation
Nov 02Mezzion Pharma Co.,Ltd.'s (KOSDAQ:140410) Shareholders Might Be Looking For Exit
Sep 27Revenues Not Telling The Story For Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
Jun 11Optimistic Investors Push Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Shares Up 26% But Growth Is Lacking
Mar 04We Might See A Profit From Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Soon
Feb 05
Mezzion PharmaLtd (KOSDAQ:140410) Shareholders Have Enjoyed A Whopping 605% Share Price Gain
Dec 14Shareholder Returns
| A140410 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -1.0% | -8.8% | -6.0% |
| 1Y | -16.7% | 9.9% | -4.4% |
Return vs Industry: A140410 underperformed the KR Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: A140410 underperformed the KR Market which returned -4.4% over the past year.
Price Volatility
| A140410 volatility | |
|---|---|
| A140410 Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A140410 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A140410's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 17 | Dean Park | www.mezzion.co.kr |
Mezzion Pharma Co.,Ltd. engages in the development, manufacturing, and sale of pharmaceutical products in South Korea. It is developing udenafil, a PDE5 protein for the treatment of erectile dysfunction, benign prostatic hyperplasia, portal hypertension, pulmonary arterial hypertension, and single heart failure diseases.
Mezzion Pharma Co.,Ltd. Fundamentals Summary
| A140410 fundamental statistics | |
|---|---|
| Market cap | ₩925.87b |
| Earnings (TTM) | -₩8.87b |
| Revenue (TTM) | ₩20.25b |
45.7x
P/S Ratio-104.4x
P/E RatioIs A140410 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A140410 income statement (TTM) | |
|---|---|
| Revenue | ₩20.25b |
| Cost of Revenue | ₩17.02b |
| Gross Profit | ₩3.22b |
| Other Expenses | ₩12.09b |
| Earnings | -₩8.87b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -295.97 |
| Gross Margin | 15.93% |
| Net Profit Margin | -43.80% |
| Debt/Equity Ratio | 0% |
How did A140410 perform over the long term?
See historical performance and comparison